CheckMate 649’s Four-Year Survival Data on Chemo + Nivolumab for Gastric & Esophageal Cancer
The four-year survival data from the CheckMate 649 study, revealed at the ASCO GI meeting, demonstrates the survival benefits of combining chemotherapy with nivolumab. This pivotal research supports the recommendation that this combination therapy should be adopted as the new standard of care for treating gastric and esophageal cancers.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
